Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 243
- Q3 2025, −47 vs. previous quarter
- 13F value
- $8.57B
- Reported value at the end of Q3 2025
- Superinvestors holding
- 2
- At the end of Q3 2025
Superinvestors holding VRNA, Q3 2025
2 superinvestors report holding Verona Pharma plc on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
2.7%
Verona Pharma plc's share of the portfolio
- Shares
- 1,002,080
- Value
- $106.9M
Soros Fund Management
George Soros
0.5%
Verona Pharma plc's share of the portfolio
- Shares
- 285,185
- Value
- $30.4M
Latest insider trades
Open-market purchases and sales by Verona Pharma plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Cunningham KennethDirector | SSale | −10.8K | $13.14 | −$142.0K | −11.9%79.8K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Deschamps LisaDirector | SSale | −9.46K | $13.14 | −$124.4K | −10.0%84.9K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Fisher AndrewGeneral Counsel | SSale | −9.58K | $13.14 | −$125.9K | −2.2%417.9K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Hahn Mark WChief Financial Officer | SSale | −208.9K | $13.14 | −$2.75M | −1.6%12.5M after | 10b5-1 |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Rickard Kathleen A.Chief Medical Officer | SSale | −58.3K | $13.14 | −$766.5K | −2.2%2.61M after | 10b5-1 |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Ackermann ChristinaDirector | SSale | −1.81K | $13.14 | −$23.8K | −2.7%64.1K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Austwick MichaelDirector | SSale | −11.3K | $13.14 | −$148.3K | −47.0%12.7K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Brady James AloysiusDirector | SSale | −824 | $13.14 | −$10.8K | −3.4%23.2K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Zaccardelli DavidPresident and CEO | SSale | −208.9K | $13.14 | −$2.75M | −1.5%13.4M after | 10b5-1 |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Ebsworth David RDirector | SSale | −1.90K | $13.14 | −$25.0K | −0.2%880.5K after |
Top 10 13F holders, Q3 2025
The largest institutional positions in Verona Pharma plc at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pentwater Capital Management LP | 5,300,000 | $565.6M | 5.08% | +5,300,000 | New |
| UBS Oconnor LLC | 4,283,462 | $457.1M | 13.74% | +4,283,462 | New |
| HBK Investments L P | 4,263,576 | $455.0M | 6.70% | +4,263,576 | New |
| BlackRock, Inc. | 3,826,710 | $408.3M | 0.01% | +3,483,014+1,013.4% | Added |
| FIL Ltd | 3,488,500 | $372.3M | 0.29% | +3,488,500 | New |
| Frazier Life Sciences Management, L.P. | 3,383,950 | $361.1M | 10.82% | 00.0% | Unchanged |
| Davidson Kempner Capital Management LP | 3,271,623 | $349.1M | 4.88% | +3,271,623 | New |
| Glazer Capital, LLC | 3,205,878 | $342.1M | 11.49% | +3,205,878 | New |
| NEA Management Company, LLC | 2,252,994 | $240.4M | 13.19% | −10,144−0.4% | Reduced |
| Goldman Sachs Group Inc | 1,935,278 | $206.5M | 0.03% | −682,019−26.1% | Reduced |